Barnard Katharine D, Kropff Jort, Choudhary Pratik, Neupane Sankalpa, Bain Stephen C, Kapitza Christoph, Forst Thomas, Link Manuela, Mdingi Colleen, DeVries J Hans
1 Faculty of Health and Social Sciences, Bournemouth University, Bournemouth, UK.
2 BHR Limited, Fareham, UK.
J Diabetes Sci Technol. 2018 May;12(3):634-638. doi: 10.1177/1932296817735123. Epub 2017 Oct 8.
Real-time continuous glucose monitoring is associated with significant benefits for diabetes management. Implantable sensors could overcome some challenges reportedly associated with device visibility, psychosocial functioning and sensor durability.
A psychosocial assessment was conducted to determine acceptability and impact of an implantable continuous glucose monitoring (CGM) sensor as part of the PRECISE trial. Questionnaires were administered to participants comprising the Diabetes Distress Scale, the CGM impact scale, and bespoke device satisfaction.
Fifty-one participants across the United Kingdom (n = 10) and Germany (n = 41) completed the questionnaires. Of these, 90% had T1D, 50% followed an insulin pump therapy regimen, and 45% of the participants were previous CGM users. CGM Impact Scale results show 86% (n = 44) of participants reported feeling better (14% neutral) about their diabetes control with 90% CGM naïve participants and 81% previous CGM users reporting increased confidence about their diabetes management. Furthermore, 73% (n = 37) felt more safe (27% neutral) while sleeping and 78% (n = 39) more confident (22% neutral) about avoiding serious hypoglycemia. Responses correspond with an average improvement in HbA1c from 7.51 to 7.05 ( P < .0001) over the 90 days use of the CGM. Overall, the system was rated highly on ease of use, convenience and comfort. 84% would choose to be inserted again with 93% of CGM naïve participants (86% previous CGM users) reporting minimized burden of diabetes.
Implantable CGM devices are acceptable to users and are evaluated favorably. The considerable majority of participants (93% of first time users and 77% previous CGM users) would like to continue using the system to help manage their diabetes more effectively.
实时连续血糖监测对糖尿病管理具有显著益处。据报道，可植入式传感器可以克服一些与设备可见性、心理社会功能和传感器耐用性相关的挑战。
作为PRECISE试验的一部分，进行了一项心理社会评估，以确定可植入式连续血糖监测（CGM）传感器的可接受性和影响。向参与者发放了问卷，包括糖尿病痛苦量表、CGM影响量表和定制的设备满意度问卷。
来自英国（n = 10）和德国（n = 41）的51名参与者完成了问卷。其中，90%患有1型糖尿病，50%采用胰岛素泵治疗方案，45%的参与者曾使用过CGM。CGM影响量表结果显示，86%（n = 44）的参与者表示对糖尿病控制感觉更好（14%无变化），90%的初次使用CGM的参与者和81%曾使用过CGM的参与者表示对糖尿病管理更有信心。此外，73%（n = 37）的人在睡觉时感觉更安全（27%无变化），78%（n = 39）的人对避免严重低血糖更有信心（22%无变化）。这些反应与CGM使用90天内糖化血红蛋白（HbA1c）从7.51平均改善至7.05（P <.0001）相对应。总体而言，该系统在易用性、便利性和舒适性方面获得了高度评价。84%的人愿意再次接受植入，93%的初次使用CGM的参与者（86%曾使用过CGM的参与者）表示糖尿病负担最小化。
可植入式CGM设备为用户所接受，并得到了积极评价。绝大多数参与者（93%的初次使用者和77%曾使用过CGM的使用者）希望继续使用该系统，以更有效地帮助管理他们的糖尿病。
